First‐in‐human study of the EZH1 and EZH2 dual inhibitor valemetostat tosylate (DS‐3201b) in patients with relapsed or refractory non‐Hodgkin lymphomas Meeting Abstract


Authors: Ishitsuka, K.; Izutsu, K.; Maruyama, D.; Makita, S.; Jacobsen, E. D.; Horwitz, S.; Kusumoto, S.; Allen, P.; Porcu, P.; Imaizumi, Y.; Yamauchi, N.; Morishima, S.; Kawamata, T.; Foss, F. M.; Utsunomiya, A.; Nosaka, K.; Serbest, G.; Kato, K.; Adachi, N.; Tsukasaki, K.
Abstract Title: First‐in‐human study of the EZH1 and EZH2 dual inhibitor valemetostat tosylate (DS‐3201b) in patients with relapsed or refractory non‐Hodgkin lymphomas
Meeting Title: 16th International Conference on Malignant Lymphoma - Virtual Edition
Journal Title: Hematological Oncology
Volume: 39
Issue: Suppl. 2
Meeting Dates: 2021 Jun 18-22
Meeting Location: Virtual
ISSN: 0278-0232
Publisher: Wiley Blackwell  
Date Published: 2021-06-01
Start Page: 38
End Page: 40
Language: English
ACCESSION: 150945341
DOI: 10.1002/hon.14_2879
PROVIDER: EBSCOhost
PROVIDER: cinahl
PUBMED: 34105791
DOI/URL:
Notes: Meeting Abstract: 14 -- Accession Number: 150945341 -- Entry Date: In Process -- Revision Date: 20210618 -- Publication Type: Article -- Supplement Title: Jun2021 Supplement S2 -- Journal Subset: Biomedical; Europe; Peer Reviewed; UK & Ireland -- NLM UID: 8307268. -- Source: Cinahl
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Steven M Horwitz
    645 Horwitz